With over 25 years’ experience in the pharmaceutical industry, Dr Reed has worked across research, Government and the private sector. At the completion of his melanoma research fellowship in Lausanne, Switzerland, Darryl relocated back to Australia where he joined the Therapeutic Goods Administration (Dept. of Health) and represented the Government on several joint industry committees. Moving to the private sector, Darryl has worked in a variety of senior roles with both Roche and Bayer, spanning regulatory and scientific affairs, medical and clinical support, product development, and sales and marketing.

Dr Reed headed up the Medical teams for Roche and Bayer Consumer Health divisions before moving into dedicated commercial roles. Dr Reed has a 19-year history with Bayer, he has extensive experience in leading strong product portfolios and heading up internal sales teams selling to health care professionals.

Tony is a co-founder of Tissue Repair. He has been actively involved in the Company’s clinical development program, across its two-phase 2B trials, commercialisation strategy, IP, manufacturing, analytical development and overall operations.

Tony holds patents in the company’s proprietary technology platform Glucoprime®.

Tony is an investment banker by background and has extensive experience across early-stage venture assets and in advising technology companies at ANZ Investment Bank and JPMorgan in their respective investment banking teams.

Tony is also a co-founder of Mable Technologies, an online health technology platform operating in the health services and aged care and disability sectors. Mable was named Australian growth technology company of the year in 2020. It was also listed in the Top 10 Deloitte Technology Fast 50 and the AFR Fast 100 list in 2021.

As Tony is a co-founder and has been a Director of Tissue Repair since the Company’s incorporation, he is considered by the Board not to be an independent director.

Dr Namjoshi has over 15 years’ experience in product development of several dosage forms with a broad knowledge base in pharmaceutical sciences, biotechnology, and medical devices. Over her career, she has held multiple leadership positions in pharmaceutical industries across Australia. She has expertise in formulation and analytical development, characterization, manufacturing, and registration of novel dermatology products. At Tissue Repair, Dr Namjoshi leads CMC development and development of CMC plans (formulation design, manufacturing process development and analytical control strategy) in accordance with product development portfolio and business strategy from preclinical to clinical development and commercialization.

Bill is a chemical operations and process specialist with extensive experience advising pharmaceutical manufacturers in drug development and manufacture, with a focus on topicals.  Bill has direct specific experience in approved wound topicals including the only topical drug approved for chronic wounds over the last 30 years.

Bill led the technical manufacturing transfer of the sterile diabetic ulcer gel product, REGRANEX Gel, from a Puerto Rico site to a New Jersey site.  REGRANEX Gel is a topical gel to treat chronic wounds and was the last wound care product approved as a drug by the FDA (approved 1997).

Bill led the process development and scale up of Purell from a limited distribution medical product to the world’s market leading hand sanitiser product.

Bill had key roles in the development and launch of Coppertone’s spray sunscreens resolving dosing and clogging issues through formula and device corrections, and the launching of McNeil’s liquid Tylenol products.

Bill was asked to work with Smith + Nephew at their biologic collagen API facility that had been unable to produce in specification material for their SANTYL^® debridement product.  Within two weeks Bill had the site producing in specification API consistently.

Dion  Cohen  is  a  Chartered  Accountant  with  over  15  years  of  experience  in  senior  finance  roles.  He  has worked  across  both listed  and  unlistedsectors  with  a  focus  on  financial  reporting,  governance,  capital management, and establishing streamlined finance functions to support growth.

Patrick Kania is a medical device executive and brings over 20 years commercialisation and leadership experience in Medical Devices, Pharma, and Health Technologies, within sales and marketing management, and general management, working across the US, Europe and APAC.

Mr Kania’s commercial experience spans large public organisations and early stage start-ups. Patryk is CEO and President USA, and Managing Director of Field Orthopaedics Ltd. He has previously held senior roles at Smith+Nephew, Abbott, J&J Medical and Roche. Patryk’s knowledge of global market access, licensing arrangements, and commercialisation of medical devices will be invaluable to the Company in co-shaping its clinical, regulatory and commercial strategy. Patryk also currently serves as non-executive director of EMVision Medical Devices Ltd (ASX:EMV).

Alistair McKeough is a lawyer who also has extensive experience as a director of private and listed corporations in many sectors, including professional services, corporate services, regulatory technology, sports technology, charities, education and biotech. He was formerly Head of Professional Services at Automic Group, where he led the legal and company secretarial teams. Mr McKeough is currently a non-executive director of Recce Pharmaceuticals Ltd (ASX:RCE). Mr McKeough will serve as Chair of TRP’s board.

Dr Kelly was the inventor of Tissue Repair’s technology 28-year background in medical research, principally in transplantation immunology and cancer research. As Head of the Transplantation Laboratories of the Department of Surgery, The University of Sydney, Dr Kelly led a research team investigating the issue of impaired wound healing in immunosuppressed transplant recipients. That work led to the finding that yeast-derived, micro-particulate β- (1-3)(1-6) glucan optimally restores normal rates of healing in incisional wounds in animals where the repair process is inhibited by immunosuppressive therapy.  Dr Kelly currently is CEO of Noxopharm limited a cancer drug development company, and acts as a Scientific Advisor to TR Therapeutics. He has been awarded an Adjunct Professorship by the University of Sydney.

Dr Kelly indirectly holds shares through an entity that he controls.

Dr. Goldman is Founder and Medical Director of Goldman Butterwick Fitzpatrick, Groff & Fabi, Cosmetic Laser Dermatology. A graduate of Boston University, Summa Cum Laude, and the Stanford University Medical School, Dr. Goldman is a Volunteer Clinical Professor in Medicine/Dermatology at the University of California, San Diego. Dr Goldman is Board Certified by both the American Board of Dermatology and the American Board of Cosmetic Surgery.
He is a fellow of the American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Academy of Cosmetic Surgery and the American Society of Liposuction Surgery. He is former President of the American College of Phlebology and President-Elect of the American Society for Dermatologic Surgery, He presently serves on the Board of Trustees for the American Academy of Cosmetic Surgery. He has authored and/or co-authored 21 Textbooks on Dermatology, Sclerotherapy, Ambulatory Phlebectomy, Cutaneous Laser Surgery, Cellulite and Dermatologic Surgery as well as over 300 peer-reviewed publications and textbook chapters.
Dr. Goldman is a recent recipient of the American Academy of Cosmetic Surgery’s 21st Century Achievement Award and the 2009 President’s Award from the American Society for Dermatologic Surgery for Outstanding Contribution in Teaching and Research. He also serves as a medical consultant to numerous companies, including Obagi Medical, SkinMedica, Allergan Medical, Merz Cosmetic, Medicis Pharmaceuticals, Lumenis Laser Corporation, New Star Lasers, and many others.

Founder and Medical Director of The Serena Group™, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School. He is recognised internationally as an expert in the field of wound healing: He has 100 published papers and has given more than 300 invited lectures throughout the world. He consults for numerous wound care industrial partners in the development of new products for the wound care space.

Dr Serena indirectly holds shares through an entity that he controls.

Dr Woodward is an expert in wound management, rehabilitation, geriatric medicine, dementia and cognitive disorders and quality use of medications. He is currently Director of Aged Care Research and heads the Wound Clinic at one of Melbourne’s large metropolitan teaching hospitals. He is past President of the Australian Wound Management Association, past Editor of Wound Practice and Research and of the Geriatric Therapeutics section of the Journal of Pharmacy Practice and Research.

Vaclav Vetvicka, Ph.D., is a Professor of Pathology at the Department of Pathology of the University of Louisville in Louisville, Kentucky, USA. He graduated from Charles University in Prague, Czech Republic with an advanced degree in biology and obtained his Ph.D. from the Czechoslovak Academy of Sciences. His postgraduate training included a stay at the Oklahoma Medical Research Foundation, Oklahoma City, OK, and at the Institute of Microbiology, Prague, Czech Republic.

His main area of research interest focuses on the development of natural immunomodulators. In addition to the glucan research, Dr. Vetvicka helped to launch glucan in several countries including USA, France, Brazil, Turkey, South Korea, Australia and Czech Republic.
Dr. Vetvicka is author and co-author of more than 360 peer-reviewed publications, ten books and nine international patents. In addition, he presented over 80 invited lectures at the universities and research institutes all around the world.